Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2024 | The evolving role of surgery after neoadjuvant immunotherapy in melanoma

Alexander Van Akkooi, MD, PhD, Melanoma Institute Australia, Sydney, Australia, comments on the evolving role of surgery in patients receiving neoadjuvant immunotherapy for melanoma. While surgery, including nodal dissection, has been standard, the PRADO study (NCT02977052) introduced exceptions by demonstrating that surgery might not be necessary in all cases. Future studies like MSLT-3 will aim to validate this approach, and ongoing research will aim to identify biomarkers or imaging techniques, such as PET scans, to further refine the need for surgery in specific patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.